ADIA Nutrition Inc. (ADIA) reports developments tied to its regenerative medicine, stem cell therapy, and biologic products business. The company operates through Adia Med clinics, which offer treatments such as PRP, AHSCT, orthopedic care, pain management, and wound repair, and through Adia Labs, which develops and sells biologic products including AdiaVita and AdiaLink.
Company news commonly covers clinical and regulatory activity involving AdiaVita, including study programs in chronic kidney disease, autism spectrum disorder, and chronic lower back pain. Updates also address operating results, product sales and medical-service revenue, capital-structure disclosures, governance matters, and the company's transition from a supplement-oriented business toward regenerative healthcare.
Adia Nutrition (OTCQB: ADIA) announced the sale of its Biolete coffee subsidiary to Cement Factory LLC on October 6, 2025, while retaining an 18% ownership stake in Cement Factory.
The move shifts Adia's focus to regenerative medicine: plans include tripling its specialized sales force in 2025, expanding Adia Med clinics, and funding R&D for next‑generation therapies. The company also cited a court‑ordered cancellation of over 25 million improperly issued shares to enhance shareholder value. Proceeds from the sale will support medical expansion; investor updates will follow via SEC filings and corporate announcements.
Adia Nutrition (OTCQB: ADIA) announced a major expansion of its sales operations by tripling its sales force and establishing four specialized teams. The restructuring creates dedicated teams for the East Coast, West Coast, Central U.S., and national/international markets to promote its Adialabs product line.
The company's portfolio includes AdiaVita (100M umbilical cord stem cells and 3T exosomes per dose), AdiaLink (3.5T exosomes per dose), and Glutaryl Transdermal Glutathione Spray. The expansion aims to enhance market reach and accessibility of these regenerative medicine products to healthcare facilities across the U.S. and globally.
Adia Nutrition Inc. (OTCQB: ADIA) has discovered over 20 million potentially improperly issued shares during an internal audit of its historical share structure. The company has initiated legal proceedings to cancel these shares and return them to the treasury. The questionable shares were issued prior to current management and lack proper documentation and regulatory compliance.
CEO Larry Powalisz emphasized the company's commitment to corporate governance and shareholder value. While addressing these historical issues, Adia continues to focus on its core business of advancing stem cell therapies, including treatments for Multiple Sclerosis, orthopedic conditions, chronic pain, and wound repair.
Adia Nutrition Inc. (OTCQB: ADIA) is finalizing in-network provider status with major health insurance companies including Humana, Florida Blue, Cigna, Medicare, and Medicaid. This strategic move aims to expand patient access to the company's regenerative stem cell therapies.
The company has already submitted applications to Humana and Cigna, initiated the process with Florida Blue, and is actively pursuing Medicare and Medicaid access. This development builds upon Adia's recent partnership with the PI Doctors Elite Community, which connects Adia Labs with over 4,000 personal injury physicians nationwide.
Adia Nutrition (OTCQB: ADIA) has been selected as a preferred vendor for the PI Doctors Elite Community, gaining access to a network of over 4,000 personal injury physicians across the United States. This strategic partnership positions Adia Labs to tap into the $50 billion personal injury care market.
Through this partnership, Adia Labs will provide its regenerative products, including AdiaVita and AdiaLink, to physicians treating injury-related conditions. A key advantage is that these therapies may be covered by auto insurance when prescribed, bypassing traditional health insurance requirements.
The partnership follows Adia's recent expansion into the $25 billion wound care market and complements their national television campaign promoting regenerative solutions.
Adia Nutrition Inc. (OTCQB: ADIA) has announced a strategic partnership between its clinical division, Adia Med, and Venture Medical to enter the $25 billion U.S. wound care market. The collaboration provides Adia Med with HCPCS billable products optimized for insurance reimbursement, targeting conditions like diabetic ulcers, venous ulcers, and pressure sores.
The partnership builds on Adia Med's existing approvals with UnitedHealthcare and Aetna, with active filings for TRICARE. Venture Medical will provide patient review and preliminary insurance verification services to streamline the reimbursement process. This expansion aligns with Adia Med's strategy to create a high-margin revenue stream while expanding access to advanced wound care solutions.
Adia Nutrition (OTCQB: ADIA) has launched its second national television campaign highlighting Adia Med's regenerative stem cell treatments at its Winter Park, Florida clinic. The campaign emphasizes U.S.-based therapies for conditions including sports injuries, orthopedic care, chronic pain, and wound repair.
The company is targeting the $25 billion wound care market and aims to make regenerative therapies more accessible domestically. Adia Med is currently in-network with UnitedHealthcare and Aetna, with pending TRICARE approval. The initiative is supported by favorable legislation like Florida's SB1768, which recognizes stem cell therapy benefits.
Adia Nutrition Inc. (OTCQB: ADIA) has announced its clinical division, Adia Med's expansion into the advanced wound care market, valued at $25.84 billion in 2025. The market is projected to reach $38.39 billion by 2034, driven by growing demand from 8.2 million Americans requiring chronic wound treatment annually.
The company will initially offer wound care services at its Winter Park, Florida clinic, with plans for expansion. Adia Med is already in-network with major insurers including UnitedHealthcare and Aetna, facilitating immediate patient access. The expansion targets high-reimbursement opportunities while addressing critical healthcare needs, particularly for diabetic foot ulcers, pressure sores, and post-surgical wounds.
Adia Nutrition Inc. (OTCQB: ADIA) has announced that its healthcare clinic, Adia Med, has received approval as a UnitedHealthcare provider, effective August 1, 2025. This strategic development positions Adia Med within the $5.3 trillion U.S. healthcare market, enabling access to its regenerative medicine treatments for UnitedHealthcare members.
Located in Winter Park, Florida, Adia Med specializes in minimally invasive therapies for orthopedic injuries, chronic pain, and wound repair. The clinic is staffed by physicians and Advanced Practice Registered Nurses (APRNs), offering personalized care using regenerative medicine treatments. The company is also seeking strategic partnerships and offering licensing opportunities for clinic owners interested in integrating Adia's regenerative therapies.
Adia Nutrition (OTCQB: ADIA) has announced its entry into the $3.9 billion glutathione market through two key initiatives. The company's subsidiary, Adia Med, is incorporating glutathione IV therapies into its treatment protocols at select clinics, complementing its existing stem cell and exosome treatments. Additionally, Adia Labs has launched Glutaryl Transdermal Glutathione Spray, utilizing sub-nanotechnology for enhanced skin absorption.
The company's expansion includes integrating glutathione with its Adia Vita treatment (featuring 100 million stem cells and 3 trillion exosomes) for various conditions including orthopedics, pain management, and wound repair. The new transdermal spray product is positioned as a high-margin offering targeting athletes, wellness enthusiasts, and individuals seeking non-invasive options.